No human studies have linked fenugreek to causing cancer, and no major safety agency has classified it as a carcinogen. The National Toxicology Program reviewed one of fenugreek’s key compounds, trigonelline, and found zero carcinogenicity data in the scientific literature. However, there is one important caveat: lab studies show fenugreek can stimulate the growth of hormone-sensitive breast cancer cells, which means it could potentially worsen an existing cancer rather than cause one from scratch.
That distinction matters. The question of whether fenugreek “causes” cancer and whether it could “fuel” certain cancers already present are two different concerns, and the evidence points in different directions depending on which one you’re asking about.
No Evidence It Causes Cancer in Healthy People
Fenugreek has been used in cooking and traditional medicine for centuries, and the FDA classifies fenugreek extract as Generally Recognized as Safe (GRAS) for use as a flavoring agent. That designation applies to amounts typically found in food. A 2025 scoping review of adverse effects reported in human clinical trials found no cancer cases linked to fenugreek supplementation. The most common side effects were mild gastrointestinal issues: reflux, abdominal pain, diarrhea, bloating, and nausea.
When the National Toxicology Program examined trigonelline, one of fenugreek’s primary alkaloids (also found in coffee), it noted the complete absence of carcinogenicity data. What it did find was one study showing the opposite: trigonelline demonstrated anticancer activity against a type of leukemia in mice.
Lab Studies Show Anticancer Properties
Much of the cancer research on fenugreek actually explores whether it could fight tumors, not cause them. Fenugreek seeds contain a plant compound called diosgenin, present at concentrations of roughly 0.1% to 0.9% of the seed by weight. In lab settings, diosgenin has shown the ability to kill cancer cells and slow their spread across several cancer types.
A study published in the American Journal of Translational Research found that fenugreek seed extract triggered programmed cell death in pancreatic cancer cells and blocked their ability to migrate, which is the process that leads to metastasis. The extract worked by disrupting the signaling pathways cancer cells rely on to grow and spread. Separately, diosgenin reduced the viability of human colon cancer cells in a dose-dependent manner, meaning higher concentrations killed more cancer cells. At certain concentrations, it cut the number of surviving colon cancer cells by half within 24 hours.
These are lab results, not human trials. Killing cancer cells in a dish is far easier than treating cancer in a living person, and no one should treat fenugreek as a cancer therapy. But they do suggest that for most people, fenugreek is more likely to have protective effects than harmful ones.
The Concern With Hormone-Sensitive Cancers
Here’s where the picture changes. Memorial Sloan Kettering Cancer Center warns that fenugreek acts as an estrogen receptor modulator, meaning it can mimic or influence the effects of estrogen in the body. In lab studies, this estrogenic activity stimulated the growth of breast cancer cells. For someone with an estrogen-receptor-positive (ER-positive) breast cancer, that’s a serious concern.
This doesn’t mean fenugreek gave those cells cancer. It means fenugreek’s estrogen-like compounds provided fuel for cancer cells that were already programmed to grow in response to estrogen. The same mechanism that makes fenugreek potentially helpful for some hormonal conditions (like supporting lactation or easing menopause symptoms) is what makes it risky when hormone-sensitive cancers are involved.
Both the Cleveland Clinic and Memorial Sloan Kettering list hormone-sensitive cancers as a clear contraindication for fenugreek supplementation. This includes not just breast cancer but potentially other estrogen-driven conditions. The concern applies specifically to supplements and concentrated extracts, which deliver far higher doses of active compounds than the pinch of fenugreek you’d use in a curry.
Food Amounts vs. Supplement Doses
The amount of fenugreek matters significantly. Using fenugreek seeds as a spice in cooking delivers a small, dilute exposure to its active compounds. Supplements, on the other hand, typically provide 500 mg to 1,800 mg of concentrated fenugreek per dose, taken multiple times daily. Some clinical protocols have used up to 7.5 grams or even higher daily doses. At those levels, the concentration of estrogenic compounds and other bioactive ingredients is meaningfully higher than what you’d get from food.
The FDA’s GRAS designation specifically covers fenugreek as a flavoring agent, not as a high-dose supplement. Most safety concerns from cancer researchers focus on supplemental doses rather than culinary use. If you cook with fenugreek occasionally, the amounts involved are unlikely to pose any cancer-related risk.
Who Should Avoid Fenugreek Supplements
For the general population, there is no credible evidence that fenugreek causes cancer. But certain groups should avoid concentrated fenugreek products:
- People with hormone-sensitive cancers, including ER-positive breast cancer, because fenugreek’s estrogenic activity can stimulate tumor cell growth.
- People taking hormonal therapies for cancer, since fenugreek could interfere with treatments designed to block estrogen.
- Pregnant women, because fenugreek has been linked to birth defects in both animal and human studies when consumed in amounts beyond normal food use.
If you have no history of hormone-sensitive cancer and you’re using fenugreek as a cooking spice or taking a standard supplement for blood sugar support or milk production, the existing evidence does not suggest a cancer risk. The caution is narrow but real: fenugreek’s estrogen-like effects can be harmful specifically when hormone-driven cancer cells are already present.